Key result
Aminoguanidine treatment in DOCA-salt hypertensive rats significantly decreased blood pressure (144 vs 176 mmHg, P<0.05) and improved cardiac contractility independent of changes in collagen content.
Why the study?
Does aminoguanidine improve cardiovascular function and structure in DOCA-salt hypertensive rats?
Does aminoguanidine improve cardiovascular function and structure in DOCA-salt hypertensive rats?
Absolute Event Rate: 144% vs 176%
p-value: p=<0.05
Aminoguanidine improves cardiovascular function and reduces diastolic stiffness in a rat model of hypertension without altering total collagen content, suggesting that collagen crosslinking is a primary driver of hypertensive cardiovascular dysfunction.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for collagen crosslinking inhibition in hypertension; human trials required before any clinical consideration.
Chan et al. (2006) studied DOCA-salt hypertension. Aminoguanidine (AG) vs. DOCA-salt rats (untreated) was evaluated on Blood pressure (p=<0.05). Aminoguanidine treatment in DOCA-salt hypertensive rats significantly decreased blood pressure (144 vs 176 mmHg, P<0.05) and improved cardiac contractility independent of changes in collagen content.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: